EBV 通过诱导 CD163⁺M2 巨噬细胞极化和 MMP9 分泌促进 TCR-T 细胞治疗耐药
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion.
MMP9 抑制剂可改善受 EBV 诱导的 M2 巨噬细胞抑制的 TCR-T 细胞功能。
MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 1 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion.
MMP9 抑制剂可改善受 EBV 诱导的 M2 巨噬细胞抑制的 TCR-T 细胞功能。
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients.
Progress in Adoptive Cell Therapy for Advanced Gastric Cancer.
Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review.
Aldehyde Dehydrogenese-1 High Cancer Stem-like Cells/Cancer-initiating Cells Escape from Cytotoxic T Lymphocytes due to Lower Expression of Human Leuk
High-36 细胞和 Low-8 细胞分别代表新型胃癌干细胞/肿瘤起始细胞(CSCs/CICs)和非干细胞/肿瘤起始细胞(非 CSCs/CICs)。ALDH 高表达的 CSCs/CICs 因 HLA I 类分子表达较低而逃避 T 细胞的攻击。
MEMBER ACCOUNT
登录成功会直接打开下一页。